RLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
RLC Labs Inc. is recalling Nature-Throid tablets due to Current Good Manufacturing Practice (CGMP) deviations. The products were manufactured under conditions found to be subpotent.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls with potential for adverse health consequences (such as subpotency) are categorized as Severe (Score 4), as they are not Class I (Critical) but involve significant quality deviations.
Plain-English summary
RLC Labs Inc. is recalling Nature-Throid, Thyroid USP tablets, which contain liothyronine (T3) and levothyroxine (T4). The recall covers 1.75 Grain (113.75 mg) tablets packaged in 30-count, 60-count, 90-count, 100-count, and 1,000-count bottles. The affected products are distributed nationwide in the United States and include all lots with expiry dates between October 2020 and July 2023.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. The source text indicates that the products were manufactured under the same conditions as those found to be subpotent. This suggests a potential issue with the potency or quality of the medication.
Consumers and healthcare providers should stop using the affected Nature-Throid tablets and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The recall is classified as FDA Class II, indicating a reasonable probability that use of the product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Nature-Throid, Thyroid USP [liothyronine (T3) 15.75 mcg and levothyroxine (T4) 66.5 mcg], 1.75 Grain (113.75 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3307-4; b) 60-count bottles, NDC 64727-3307-5; c) 90-count bottles, NDC 64727-3307-6; d) 100-count bottles, NDC 64
- Manufacturer
- RLC Labs Inc.
- Category
- Drug — Thyroid Hormone
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots with expiry between 10/2020-07/2023
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 24 recalled by RLC Labs Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 24 products in this recall →Related recalls
Same manufacturer · RLC Labs Inc.
See all →- SevereRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- ModerateRLC Labs Recalls WP Thyroid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
- SevereRLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-23
Same hazard · subpotency
See all →- ModerateGood Neighbor Pharmacy Earwax Removal Drug Recalled for Low Potency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22
- ModerateFoster & Thrive Carbamide Peroxide 6.5% Recalled for Subpotent Strength
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateMeijer Earwax Removal Kit Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2026-07-22